Solventum
Solventum Corporation (NYSE: SOLV) is a global healthcare company that develops, manufactures and commercializes products and software for patient care and healthcare operations. Its customers include hospitals, physicians, clinics, dental practices and other healthcare providers. MedSurg accounted for 57.9% of 2025… From the company’s description.
In fiscal 2025, Solventum reported revenue of $8.32B, up 0.9% from fiscal 2024, and net income of $1.56B. Its operating margin was 26.2%, and operations generated $369.00M in cash. Over the twelve months to Jun 30, 2026, revenue was $8.31B.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Solventum does
In the company’s own words
Solventum Corporation (NYSE: SOLV) is a global healthcare company that develops, manufactures and commercializes products and software for patient care and healthcare operations. Its customers include hospitals, physicians, clinics, dental practices and other healthcare providers. MedSurg accounted for 57.9% of 2025 sales and includes wound care, skin care, surgical supplies, sterilization assurance, temperature management and medical devices. Dental Solutions, representing 16.2% of 2025 sales, offers products such as orthodontic brackets and aligners, restorative cements and bonding agents. Health Information Systems, at 16.3% of 2025 sales, provides software for clinical documentation, coding, revenue-cycle automation, speech recognition and data visualization. Solventum sells in more than 90 countries through direct sales, distributors, key accounts and e-commerce. It had approximately 20,000 employees in 2025. The company became a standalone public company following its spin-off from 3M and continues to use some 3M infrastructure under transition agreements. Its website is https://www.solventum.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Surgical & Medical Instruments
- Headquarters
- EAGAN, MN
- Fiscal year end
- December
- CIK
- 1964738
- SIC
- 3841
Financial performance, year by year
Fiscal 2024–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Solventum — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in Solventum · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · Solventum’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Solventum’s bonds, as funds hold them
Funds report holding 5 issues of Solventum’s debt, $1.11B at market value — what funds hold, not the company’s total debt. Weighted-average coupon 5.57%, maturing 2027 to 2054.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Solventum and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Solventum's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Solventum's last four quarterly filings that the numbers alone won't show?”